SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community scrutinizes the CEO's recent national television appearance and the implications of a newly published study on leukemia survival outcomes. Investors are actively debating whether these events signal imminent clinical milestones, such as a trial data readout, or are simply strategic moves to increase institutional awareness while the company remains in a quiet period.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heavy volatility as investors weigh a strong earnings beat against concerns over the company's aggressive AI capital expenditure plans and potential dilution. While the community is debating whether the stock is primed for a major breakout or a sharp flush, sentiment remains divided between those pointing to record revenue growth and those fearing the market's cold reaction to increased spending.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as the community debates the implications of a negative CHMP opinion for its drug arimoclomol, with investors actively discussing the company's decision to pursue a re-examination process. While some express frustration over the regulatory setback, many shareholders remain focused on the company's strong cash position, ongoing U.S. commercialization, and the potential for a strategic buyout or value recovery.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors digest the company's latest earnings report, which featured an adjusted profit beat and raised full-year guidance despite a headline profit decline due to restructuring costs. Community discussion centers on the stock's dividend stability, share repurchases, and the potential for long-term growth driven by AI infrastructure and subscriber gains.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending as investors react to an FDA advisory committee's decision to recommend several peptides for inclusion on the compounding list, fueling excitement about the company's potential to expand its wellness and growth offerings. The community is actively debating the significance of these regulatory updates, with strong discourse centered on the stock's high short interest and the potential for a short squeeze despite skepticism from notable critics.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is facing intense selling pressure as investors react to ongoing concerns about declining broadband subscribers and high debt levels, driving the stock to multi-year lows. While some contrarian investors are actively discussing a potential short squeeze fueled by an aggressive share repurchase program, the broader community remains polarized between those betting on a deep-value turnaround and those focused on the persistent downward trend.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as investors react to a significant earnings beat and robust guidance driven by accelerating demand for optical data center infrastructure. The community is actively debating the stock's valuation and volatility, with many traders closely monitoring the momentum-driven price action and the impact of the company's expanding AI-focused product portfolio.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor is trending as investors weigh an earnings beat driven by strong HOKA and UGG momentum against ongoing concerns regarding guidance and broader sector headwinds. The community is actively debating the company's valuation and capital efficiency, with many retail traders dismissing the recent price dip as an overreaction, while some analysts remain cautious about the long-term impact of tariffs and competitive pressures.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares are trending following a Trump administration proposal to cap credit card interest rates at 10%, sparking investor debate over the potential impact on lending revenue and credit availability. While community sentiment remains divided between concerns over profit margins and optimism regarding the company's premium, spend-centric model, many are closely watching the stock for volatility as market participants assess regulatory risks versus long-term business fundamentals.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing extreme volatility and massive trading volume as the community debates whether the heavy activity signals institutional accumulation or ongoing market manipulation. Investors are increasingly focused on the stock's significant short interest and strategic pivot toward agentic AI, with many monitoring for a potential breakout above key resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement Grant PR Newswire LAUSANNE, Switzerland, July 1, 2026 LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ --ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial PR Newswire LAUSANNE, Switzerland, June 30, 2026 100 r/r DLBCL patients treated at the selected 150...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire...

ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details

Equity

ADC Therapeutics expects to generate annualized cost savings of about $10 million and incur one-time pre-tax charges of about $3 million.

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities PR Newswire LAUSANNE, Switzerland, June 24, 2026 Planned ~17...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 18, 2026 NEW YORK, June 18, 2026 /PRNewswire...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026 /PRNewswire...

ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)

U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.67%, other stocks also slide.read more...

Why Is ADC Therapeutics Stock Falling On Friday?

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street analyst slashes targets due to serious trial safety signals.read more...

ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data

ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, despite meeting its primary efficacy goal.

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Adc Therapeutics SA

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADCTAdc Therapeutics SA

Fundamentals

Latest ADCT News